Michael G Fehlings, PhD, MD, FACS, FRCSC

Follow Dr. Fehlings:
  1. Neuroprotection of the injured spinal cord
  2. Regenerative medicine for spinal cord injury (SCI) using stem cell and tissue engineering approaches
  3. Mechanisms of glial-axonal signalling using electrophysiological and imaging approaches
  4. Spinal cord and brain repair with a focus on Cerebral Palsy
  5. Developing and characterizing animal models of cervical spondylotic myelopathy (CSM), the most common cause of spinal cord dysfunction, and examining strategies for improving outcomes in this condition
  6. Clinical trials bringing lab-tested therapeutics to clinic
Our laboratory integrates molecular, imaging, electrophysiological and neurobehavioural approaches to examine the pathophysiology and treatment of central nervous system injury, using spinal cord injury as a model system. Current studies in SCI are focused on understanding the mechanisms of the secondary injury after SCI with a focus on examining the role of inflammation, development of novel neuroprotective strategies and the use of stem cell transplantation strategies to repair the spinal cord. The translation from benchside to bedside is a key goal of our research and is exemplified in the team's involvement in clinical trials.

Our laboratory plays a leading role in SCI-NET (Spinal Cord Injury New Emerging Team)--a unique, interdisciplinary team of clinicians and scientists with expertise in micro-neurosurgery and neurotrauma (Fehlings and Tator, UHN), stem cell and growth factor biology (van der Kooy, Nagy and Morshead, University of Toronto), tissue engineering and nanotechnology (Shoichet, University of Toronto).

SCI-NET is examining three integrated strategies to treat SCI:

  1. Application of experimental models of cervical SCI for regenerative therapeutics
  2. Determine the efficacy of exogenous stem cell mediated recovery following cervical SCI 
  3. Determine the efficacy of pharmacologically stimulated endogenous stem cell mediated recovery following cervical SCI
  4. Explore combinatorial treatments for cervical SCI involving chABC and endogenous/exogenous cells
The SCI-NET team is a key part of the regenerative medicine program at the McLaughlin Center for Molecular Medicine which provides an excellent, collaborative research environment.

A more recent area of research is a forward and reverse translation investigation of therapies for Cerebral Palsy. In this study, the focus is on more fully understanding the underlying mechanisms of constraint induced movement therapy (CIMT), which is already in use in the clinic, in order to optimize timing and duration. In addition, the team will study stem cell therapies as a means of augmenting therapies already in use.

Finally, Dr. Fehlings is involved with several clinical trials:

  1. Examining the use of Riluzole in cervical spondylotic myelopathy (CSM), a common spinal condition
  2. Examining the use of Riluzole in spinal cord injury (RISCIS)
  3. Approaches for the treatment of metastatic epidural spinal cord compression and CSM
  4. Surgical Timing in Acute Spinal Cord Injury Study (STASCIS) (published)
  5. Transplantation of stem cells for spinal cord injury
PLoS One. 2018;13(9):e0204082
Martin AR, De Leener B, Cohen-Adad J, Kalsi-Ryan S, Cadotte DW, Wilson JR, Tetreault L, Nouri A, Crawley A, Mikulis DJ, Ginsberg H, Massicotte EM, Fehlings MG
Spine J. 2018 Aug 14;:
Tuchman A, Lenke LG, Cerpa M, Fehlings MG, Lewis SJ, Shaffrey CI, Cheung KMC, Carreon LY, Dekutoski MB, Schwab FJ, Boachie-Adjei O, Kebaish K, Ames CP, Qiu Y, Matsuyama Y, Dahl BT, Mehdian H, Pellisé F, Berven SH
Stem Cells Transl Med. 2018 Aug 07;:
Nagoshi N, Khazaei M, Ahlfors JE, Ahuja CS, Nori S, Wang J, Shibata S, Fehlings MG
J Neuroinflammation. 2018 Aug 03;15(1):219
Badner A, Hacker J, Hong J, Mikhail M, Vawda R, Fehlings MG
J Neurotrauma. 2018 Aug 15;35(16):1942-1957
Cadotte DW, Akbar MA, Fehlings MG, Stroman PW, Cohen-Adad J
Nat Commun. 2018 Jul 26;9(1):3000
Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW
Int J Mol Sci. 2018 Jul 25;19(8):
Hong J, Chang A, Zavvarian MM, Wang J, Liu Y, Fehlings MG
Cancer. 2018 Jul 05;:
Nater A, Tetreault LA, Kopjar B, Arnold PM, Dekutoski MB, Finkelstein JA, Fisher CG, France JC, Gokaslan ZL, Rhines LD, Rose PS, Sahgal A, Schuster JM, Vaccaro AR, Fehlings MG
Spine (Phila Pa 1976). 2018 Jul 01;43(13):905-912
Kato S, Fehlings MG, Lewis SJ, Lenke LG, Shaffrey CI, Cheung KMC, Carreon LY, Dekutoski MB, Schwab FJ, Boachie-Adjei O, Kebaish KM, Ames CP, Qiu Y, Matsuyama Y, Dahl BT, Mehdian H, Pellisé F, Berven SH

Pages


 

Head, Spinal Program, Toronto Western Hospital, UHN
McEwen Centre for Regenerative Medicine, UHN
Professor, Department of Surgery, University of Toronto
Vice Chair Research, Department of Surgery, University of Toronto
Co-Director, Spine Program, University of Toronto
Member, Institute of Medical Science, University of Toronto
McLaughlin Center in Molecular Medicine, University of Toronto